Olema Pharmaceuticals, Inc. - 8-K Filing
Olema Pharmaceuticals reported Q1 2026 financial results with $53.1 million net loss compared to $30.4 million in the same period last year due to increased clinical development spending and personnel costs, including a $3.3 million rise in non-cash stock-based compensation for R&D expenses. The company ended Q1 2026 with $505.3 million in cash, cash equivalents, and marketable securities. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $OLMA